Aesthetic PulseA serialised briefing for the UK aesthetics sector Published by Northbank Media
SerialNo. 001–016
Standing reference Reviewed 2026-08-01

How a dermal filler is regulated, and what that regulation does not tell you

A standing reference on dermal filler regulation in the UK: the medical device route, what conformity assessment establishes, and the questions it leaves open.

Standing references· Published by Northbank Media·British English
Crystalline growth from a nucleus. Scientific macro, no product and no clinic.
Crystalline growth from a nucleus. Scientific macro, no product and no clinic.
The short answer

Most dermal fillers placed on the UK market are regulated as medical devices under the Medical Devices Regulations 2002 as amended, with the MHRA as regulator and different arrangements applying in Great Britain and Northern Ireland. Conformity assessment establishes that a manufacturer has followed the route appropriate to the device's classification for its stated intended purpose. It does not establish that a product achieves a particular cosmetic result, that it is superior to any other product, or that a practitioner is competent to inject it.

The most common category error in aesthetics marketing is treating device regulation as though it were medicines regulation. They are different regimes with different evidential requirements, and the difference matters to a patient trying to work out what a claim actually means.

The route to market

A medical device reaches the UK market through conformity assessment appropriate to its risk classification, evidenced by a marking. Higher risk classifications require the involvement of a notified or approved body. Some lower risk classifications can rest on the manufacturer's own declaration of conformity.

The classification is driven by the device's characteristics and its intended purpose, and injectable products intended to modify the appearance sit in the higher risk end of the classification structure. But the general point stands: conformity assessment is a process demonstrating that requirements have been met for a stated intended purpose. It is not the marketing authorisation process a medicine undergoes, and it does not involve an authority determining that a product produces a particular cosmetic outcome.

ObservedThe MHRA publishes guidance on how medical devices comply with the legal requirements in the UK, covering classification, conformity routes and the role of approved bodies.

Great Britain and Northern Ireland are not the same market

Under the Windsor Framework arrangements, Great Britain and Northern Ireland operate on different footings for medical devices. That means the applicable requirements and the acceptable markings can differ depending on where the product is placed on the market.

For a clinic, this is a supply chain question rather than a clinical one, and it is another reason that any statement about UK device regulation which does not distinguish the two is incomplete.

What conformity assessment does establish

That a manufacturer exists and is identifiable. That the product has a stated intended purpose. That relevant essential requirements have been addressed for that purpose. That, at the higher classifications, an independent body has been involved in assessing that. And that a route exists through which incidents can be reported and, if necessary, action taken by the regulator.

Those are real assurances and it would be wrong to dismiss them. A product with no identifiable manufacturer, no stated intended purpose and no conformity route is a materially different proposition, and products of that kind do circulate.

What it does not establish

It does not establish that the product produces a particular aesthetic result in a particular anatomical area. It does not establish superiority over any other product. It does not establish longevity claims made in marketing. It does not establish that the product can be corrected or reversed, which depends on the chemistry. And it says nothing whatever about the competence of the person injecting it, which is the variable that most determines the outcome.

What this means

The distinction that matters to a patient: the regulation is about the product's route to market, and almost everything that determines their outcome is about the practitioner, the assessment and the technique. A conformity mark is a fact about a box, not a fact about a face.

Reading filler claims

"MHRA approved." The agency does not approve devices in the way it authorises medicines. This phrasing misdescribes the regime and it is extremely common.

"Medical grade." Not a regulatory category. It is an adjective performing the work of a classification.

"Fully dissolvable." Depends entirely on the chemistry. Some filler types can be broken down enzymatically and some cannot, and the general claim is made far more often than it is true.

"Clinically proven." Requires evidence for the specific product, in the specific application, for the specific outcome claimed. It is an advertising claim requiring substantiation, not a synonym for regulated.

"Natural" and "biocompatible." Neither is a regulatory classification and neither conveys anything actionable about risk.

ObservedObjective claims in advertising require substantiation appropriate to the claim, which for a product performance claim means evidence about that product in that application.SpeculationPost Brexit divergence in device regulation could reduce the number of products economically viable in a market the size of the UK. If that happens it would present as narrowing choice rather than as a visible regulatory event.

What to ask, as a clinic or as a patient

What is the product, and who manufactures it. What is its stated intended purpose, and does the proposed use match it. Under what route did it reach the UK market, and is documentation available. What is the chemistry, how long is it expected to persist, and can it be corrected. And who is injecting it, on what register, with what experience of the specific area being treated.

The last question is the one that most affects the outcome, and it is the one the regulatory framework has the least to say about.

The question device regulation is genuinely useful for

Products with no identifiable manufacturer, no stated intended purpose, no conformity documentation and no traceable supply chain do circulate, and they are the situation in which the regulatory framework earns its keep.

A product bought outside a documented supply route may be counterfeit, may be a different formulation from what the packaging states, may have been stored outside its required conditions, and cannot be traced if something goes wrong. None of those risks is visible at the point of injection, and none is detectable by the patient at any point.

This is why the supply chain question matters more than the brand question. Where was this obtained from, is there documentation, and can a batch be traced back if it needs to be. Those are dull questions and they address a real risk, unlike most of the questions the sector's marketing invites patients to ask.

If something goes wrong

Adverse incidents involving medical devices, including dermal fillers, can be reported to the MHRA through the Yellow Card scheme, by professionals and by patients. It is the only national signal detection mechanism covering this territory and it is substantially underused by this sector.

No commercial links on this page

This article contains no commercial links of any kind. No affiliate links, no sponsored placements, and no links to any clinic, practitioner, agency, brand, product or retailer. Nobody paid for it, nobody previewed it and nobody outside the editorial team saw it before publication.

This publication does not name, rank or rate clinics, practitioners or agencies, because it has assessed none of them. Our funding is set out in full on the about page, the sponsor position is on the sponsorship page, and our commitments are in our editorial standards.

This is trade analysis, not medical or legal advice.

Sources

We cite legislation, regulators, public registers and clinical institutions, and we link them so the current position can be checked directly. We do not link to clinics, agencies or retailers. Where our summary and a linked primary source disagree, the source governs.

Frequently asked questions

Are dermal fillers approved by the MHRA?

Not in the sense that phrase implies. Most fillers are regulated as medical devices, which reach the market through conformity assessment appropriate to their classification rather than through the marketing authorisation process a medicine undergoes. MHRA approved is a common phrasing that misdescribes the regime.

What does conformity assessment actually establish?

That an identifiable manufacturer has followed the route appropriate to the device's classification, addressing the relevant requirements for the product's stated intended purpose, with independent involvement at higher classifications. It does not establish a particular cosmetic outcome, superiority over other products, or the competence of whoever injects it.

Are all dermal fillers reversible?

No. Persistence and the availability of correction depend on the chemistry of the specific product. Some can be broken down enzymatically and some cannot. A general claim that fillers are dissolvable is not accurate as a category statement and should be checked against the specific product.

Do the same device rules apply throughout the UK?

Not identically. Great Britain and Northern Ireland are on different footings for medical devices under the Windsor Framework arrangements, which can affect applicable requirements and acceptable markings depending on where a product is placed on the market.

How are problems with a filler reported?

Through the MHRA Yellow Card scheme, which accepts reports of adverse incidents involving medical devices as well as adverse reactions to medicines, from healthcare professionals and from patients. It is the only national reporting route covering this territory and it is substantially underused in this sector.

The briefing, when the next issue is published

The current issue is free. One email when a new numbered issue is published, and a note when a standing reference is revised, with the date and what changed. No treatment offers, no clinic recommendations and no rankings, because we publish none of those.